Theramex announces license agreement for Prolia biosimilar in Europe and Australia

On Thursday Theramex announced that it has entered into an agreement to register and commercialize denosumab, a biosimilar of Enzene Bioscience’s Prolia®, which treats osteoporosis by decreasing bone absorption. The agreement licenses Theramex to market the drug for use in Europe and Australia.  Enzene will exclusively supply the finished product to Theramex for the duration of the agreement.